Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.27393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Kimberly Pasley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: The Clinical and Translational Intramural Funding Program through the Abigail Wexner Research Institute at Nationwide Children's Hospital.
Abstract (Originalsprache)
Background
Research studies are conflicting regarding new highly effective modulators and the association with mental health symptoms for adults and adolescents with cystic fibrosis (CF). For younger children, small studies and case reports indicate a wide range of effects, ranging from improvement in mood to the development of neuropsychiatric symptoms. However, a large placebo‐controlled study indicated no causal connection. This study evaluates the frequency and severity of mental health symptoms in children and adolescents while taking elexacaftor/tezacaftor/ivacaftor (ETI).
Methods
The study includes 81 pediatric patients with CF followed at Nationwide Children's Hospital (NCH). Patient Reported Outcomes Measurement Information System (PROMIS)‐Anxiety and Depression, Patient Health Questionnaire 8 (PHQ‐8) and Generalized Anxiety Disorder Questionnaire (GAD‐7) were used to screen for depression and anxiety. Age‐appropriate questionnaires were completed over the first 18 months after initiating ETI.
Results
At baseline, majority of participants reported mental health symptoms within normal limits (WNL). For participants with elevated baseline measures, depressive and anxiety symptoms significantly decreased throughout the study period. Depending on the metric, patients experiencing depressive and anxiety symptoms dropped to 2−3% ( n = 1, on each depressive measure) and 0% ( n = 0, on either anxiety measures) respectively by 18 months.
Conclusion
Most pediatric patients with CF did not endorse symptoms of depression or anxiety disorders at ETI initiation. Over the first 18 months of ETI usage, the percentage of patients with these symptoms decreased, suggesting that the percentage of patients experiencing severe symptoms of depression and anxiety may decrease with ongoing use of ETI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Sleep Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Psychiatry, Institute of Living, Hartford, Connecticut, USA.
- Department of Psychiatry, University of Connecticut, Hartford, Connecticut, USA.
Förderung
- The Clinical and Translational Intramural Funding Program through the Abigail Wexner Research Institute at Nationwide Children's Hospital
Zitieren
APA
Pasley, K., Eisner, M., Sliemers, S., Young, R., Dell, M. L., McCoy, K. S., & May, A. (2025). Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27393
Vancouver
Pasley K, Eisner M, Sliemers S, Young R, Dell ML, McCoy KS, et al. Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27393
BibTeX
@article{Pasley2025,
author = {Pasley, Kimberly and Eisner, Mariah and Sliemers, Stephanie and Young, Rylie and Dell, Mary Lynn and McCoy, Karen S and May, Anne},
title = {Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.27393}
}
EUVIMED